We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
-10.1%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$792M
AUM Growth
-$198M
Cap. Flow
-$87.5M
Cap. Flow %
-11.05%
Top 10 Hldgs %
71.73%
Holding
49
New
10
Increased
7
Reduced
13
Closed
11
Avg Time Held Equity + Options
3.5 quarters
Top 10 Avg Time Held Equity + Options
4 quarters
Top 20 Avg Time Held Equity + Options
3.2 quarters
Avg Time Held Equity only
3.5 quarters
Top 10 Avg Time Held Equity only
4.5 quarters
Top 20 Avg Time Held Equity only
3.3 quarters

Top Buys

Rank Stock Value
1
PRTA icon
Prothena Corp
PRTA
+$77.3M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$22.4M
3
SLDB icon
Solid Biosciences
SLDB
+$19M
4
XCUR icon
Exicure
XCUR
+$14.1M
5
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$10.1M

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$75.8M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$51.9M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$23.7M
4
KURA icon
Kura Oncology
KURA
+$22M
5
GOSS icon
Gossamer Bio
GOSS
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.64%
2 Miscellaneous 5.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
XNCR icon
1
Xencor
XNCR
$1.75B
$84.4M 10.66%
2,501,557
+165,000
+7% +$6.59M
2018 Q4
3 quarters
PRTA icon
2
Prothena Corp
PRTA
$429M
$73.9M 9.33%
9,426,640
+8,703,340
+1,203% +$77.3M
2018 Q4
3 quarters
ONCE
3
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$69.3M 8.75%
714,789
+100,661
+16% +$10.1M
2018 Q3
4 quarters
KURA icon
4
Kura Oncology
KURA
$874M
$61.3M 7.74%
4,041,953
-1,234,800
-23% -$22M
2015 Q4
15 quarters
ARGX icon
5
argenx
ARGX
$50.5B
$60.5M 7.64%
531,165
-50,000
-9% -$6.76M
2018 Q4
3 quarters
DRNA
6
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$56.9M 7.19%
3,962,978
+646,571
+19% +$9.24M
2017 Q1
10 quarters
KYNB icon
7
Kyntra Bio
KYNB
$23.8M
$47.8M 6.04%
51,752
-8,719
-14% -$9.58M
2014 Q4
19 quarters
IRWD icon
8
Ironwood Pharmaceuticals
IRWD
$593M
$40.1M 5.06%
4,671,408
– –
2015 Q4
15 quarters
MORF icon
9
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$39.1M 4.94%
2,161,520
-105,284
-5% -$2.21M
2019 Q2
1 quarter
SLDB icon
10
Solid Biosciences
SLDB
$624M
$34.6M 4.36%
222,846
+167,713
+304% +$19M
2019 Q2
1 quarter
PRVL
11
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$29.4M 3.71%
2,392,556
– –
2019 Q2
1 quarter
KYNB icon
12
CALL
Kyntra Bio
KYNB
$23.8M
$24.1M 3.05%
26,100
+15,000
+135% +$16.5M
2017 Q4
7 quarters
HARP
13
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$20M 2.52%
146,342
+11,500
+9% +$1.62M
2019 Q1
2 quarters
BCEL
14
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$18.1M 2.29%
1,481,411
-5,568
-0.4% -$84.6K
2019 Q2
1 quarter
CHMA
15
DELISTED
Chiasma, Inc. Common Stock
CHMA
$15.1M 1.9%
3,043,827
– –
2018 Q3
4 quarters
SRPT icon
16
Sarepta Therapeutics
SRPT
$1.74B
$14.3M 1.8%
+189,745
New +$22.4M
2019 Q3
0 quarters
XCUR icon
17
Exicure
XCUR
$7.53M
$14M 1.76%
+36,768
New +$14.1M
2019 Q3
0 quarters
GOSS icon
18
CALL
Gossamer Bio
GOSS
$59.7M
$13.4M 1.7%
+10,000
New +$15.9M
2019 Q3
0 quarters
EIGR
19
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$10.9M 1.37%
35,335
-2,533
-7% -$823K
2018 Q2
5 quarters
KRSA
20
Korsana Biosciences, Inc. Common Stock
KRSA
$1.44B
$9.41M 1.19%
5,544
– –
2019 Q2
1 quarter
NXTC icon
21
NextCure
NXTC
$28.7M
$7.73M 0.98%
+20,875
New +$6.79M
2019 Q3
0 quarters
RCUS icon
22
Arcus Biosciences
RCUS
$2.87B
$6.87M 0.87%
754,505
-733,700
-49% -$5.9M
2018 Q1
6 quarters
CRIS icon
23
Curis
CRIS
$1.49M
$6.68M 0.84%
7,456
– –
2018 Q4
3 quarters
NGNE icon
24
Neurogene
NGNE
$431M
$6.46M 0.82%
113,294
– –
2018 Q2
5 quarters
ASMB icon
25
CALL
Assembly Biosciences
ASMB
$414M
$4.9M 0.62%
41,525
– –
2019 Q2
1 quarter
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2019 Portfolio in Review

As of Q3 2019, EcoR1 Capital held 49 positions worth $792M, down 20% from $990M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

EcoR1 Capital withdrew a net $87.5M in Q3 2019, closing 11 positions and reducing 13 holdings. Its most notable exit was CRISPR Therapeutics, an estimated $75.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in Sarepta Therapeutics worth $14.3M.

  • EcoR1 Capital's largest Q3 2019 buy was Sarepta Therapeutics: 189,745 shares worth $14.3M.
  • EcoR1 Capital added most to Prothena Corp in Q3 2019, an estimated $77.3M increase.
  • EcoR1 Capital's biggest Q3 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $51.9M.
  • EcoR1 Capital fully exited CRISPR Therapeutics in Q3 2019, selling an estimated $75.8M.
  • EcoR1 Capital's ten largest holdings make up 72% of its $792M portfolio in Q3 2019.
  • EcoR1 Capital opened 10 new positions and closed 11 in Q3 2019.
  • EcoR1 Capital's portfolio value fell 20% quarter-over-quarter to $792M.

Based on EcoR1 Capital's 13F filing for Q3 2019, filed 14 Nov 2019.